drugset / Trial / NCT00500370

A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients

NCT00500370

Phase 2 Completed 163 enrolled AstraZeneca Eli Lilly and Company · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a multicenter study designed to compare the effect of exenatide plus a lifestyle modification plan versus placebo plus a lifestyle modification plan on weight loss in non-diabetic, obese subjects.

Timeline

Start
2007-06
Primary completion
2008-02
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide 5 ug Subcutaneous
Subject Exenatide Peptide 10 ug Subcutaneous

Indications